The oncogenic fusion protein E2A-HLF is a chimeric transcription factor that arises from the t(17;19) translocation in childhood B-cell acute lymphoblastic leukemias (B-precursor ALL) and is associated with very poor outcome. We show that retroviral-mediated expression of E2A-HLF alone is sufficient to immortalize primary lymphoid progenitors. We identify Lmo2 and Bcl-2 as direct target genes downstream of E2A-HLF. We use real-time PCR analysis to show that LMO2 and BCL-2 expression is preferentially upregulated both in biopsy material from t(17;19) B-precursor ALL patients and lymphoid cell lines derived from t(17;19) leukemias. Co-expression of Lmo2 and Bcl-2 was sufficient to immortalize lymphoid progenitor cells resulting in a similar phenotype to that induced by E2A-HLF alone. Both shRNA-mediated knockdown of Lmo2 expression and pharmacological inhibition of BCL-2 function in E2A-HLF immortalized cells severely compromised their viability. These data suggest that both Lmo2 and Bcl-2 are required for the action of E2A-HLF in leukemogenesis.
Introduction
The t(17;19) (q22;p13) translocation occurs as a non-random translocation in approximately 1% of childhood B-lineage acute lymphoblastic leukemia (B-precursor ALL). 1 This translocation results in the formation and expression of the chimeric transcription factor E2A-HLF. 2, 3 The transforming activity of E2A-HLF has been shown to require at least one of the two trans-activation domains of E2A, as well as the DNA-binding region and the leucine zipper dimerization domain of HLF, [4] [5] [6] [7] [8] supporting the idea that E2A-HLF functions through the abnormal localization of the trans-activating domains of E2A at HLF consensus sites to induce leukemia. 9 E2A-HLF has been shown to immortalize murine hematopoietic progenitor cells (HPCs) with a myeloid phenotype, but could only immortalize HPCs with a lymphoid phenotype when co-expressed with Bcl-2 and grown on a supporting stromal layer. [10] [11] [12] The concept of 'oncogene addiction' has been proposed to explain the observation that some cancers are dependent on a small number of genes, or even a single gene, for both maintenance of the malignant phenotype and cell survival. 13 For instance, switching off expression of the BCR-ABL oncogene in mice reverses the leukemic phenotype.
14 Therefore, inhibiting the activity of one or two key target genes required for the leukemic phenotype could inhibit cancer cell growth and translate to improved outcome. These targets can either be activated oncogenes or their downstream targets. 15 The 'oncogene addiction' model also implies that overexpression of a few key downstream targets, of an initiating oncogenic lesion, could recapitulate the cancer phenotype. Therefore, the identification of genes that have altered expression in leukemogenesis by E2A-HLF and which are directly involved in tumor initiation and maintenance will be instrumental for identifying crucial therapeutic targets.
Previous screens have used t(17;19)-positive cell lines that had been transfected with a zinc-inducible vector encoding a dominant-negative suppressor of the oncoprotein to discover downstream targets. [16] [17] [18] [19] Candidate target genes were identified, however, the dominant-negative form does not completely abolish the transactivation activity of promoter-bound E2A-HLF. 20 By necessity, these screens were biased towards identifying targets more dependent on the transactivation domains of E2A and less on the DNA-binding activity of HLF, as was the case for the previously identified Groucho-related genes. 18 To complement these previous screens, we aimed to identify potential target genes, the expression of which was rapidly changed in the presence of E2A-HLF. To achieve this, we used an in vitro-inducible system to express E2A-HLF in the BaF3 cell line combined with DNA microarrays. We identified several novel targets of E2A-HLF, in particular Lmo2 and Bcl-2, the co-expression of which was sufficient to immortalize HPCs with a pre-B-cell phenotype similar to that caused by E2A-HLF expression alone. Retroviral-mediated shRNA knockdown of either Lmo2 expression or inhibition of BCL-2 family function, or both, inhibit the survival of E2AFHLF-immortalized cells. We also found that LMO2 and BCL-2 were preferentially highly expressed in primary B-precursor ALL biopsy material from t(17;19) patients compared with non-t(17;19) controls. Overall these data suggest that targeting of specific downstream targets of E2A-HLF is feasible and may provide a novel approach to treating patients with t(17;19) leukemia, which has hitherto proved fatal. 1, 21, 22 Materials and methods
Microarray Analysis
Tetracycline-inducible (Tet-On) BaF3 cell lines that inducibly expressed E2A-HLF were generated as previously described. 23 Three E2A-HLF clones were seeded at 2 Â 10 5 cells/ml in fresh medium for 12 h before culturing ± doxycycline for 12 h. Target preparation and hybridization of the Affymetrix MG-U74Av2 microarrays were conducted according to standard protocols and data were analyzed using Genespring 5.1 software (Agilent Technologies, Cheshire, UK).
Patient samples
Patient samples were collected with informed consent and ethical review board approval in accordance with the Declaration of Helsinki. RNA was isolated from ALL cells recovered from cryopreserved anonymized samples using standard protocols.
Retroviral constructs
N-terminal Myc-epitope-tagged E2A-HLF was generated by PCR using forward primer (5 0 -ATATGAATTCCACCATGGAACA AAAACTTATTTCTGAAGAAGATCTGATGAACCAGCCGCAGA GG-3 0 ) and reverse primer (5 0 -ATATGAATTCTACAGGGGCCC GTGCCT-3 0 ). The PCR product was digested with EcoRI and ligated into the EcoRI site of pMSCV-based vectors (BD Biosciences, Oxford, UK). 3 0 Myc-tagged murine Bcl-2 was generated by RT-PCR from murine thymocyte RNA and cloned into the EcoRI site of pMSCVpuro. C-terminal Myc-tagged Lmo2 was generated using IMAGE clone 11888-H17 encoding murine Lmo2 cDNA using forward primer 5 0 -ATATGAATTCCACCATG GAACAAAAACTTATTTCTGAAGAAGATCTGATGTCCTCGGCC ATCGAAAG-3 0 and reverse primer 5 0 -ATATGAATTCTAGATGA TCCCATTGAT-3 0 (the Myc tag is in italics) and cloned into the EcoRI site of pMSCVneo.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the EZ ChIP Chromatin Immunoprecipitation Kit (Upstate, Hertfordshire, UK). 1 Â 10 7 BaF3 cells transduced with E2A-HLF or Neo control were cross-linked in 1% formaldehyde in culture medium for 10 min at 37 1C, and was ChIP carried out with specific antibody (mouse anti-Myc monoclonal 4A6, Upstate) or a non-specific antibody (mouse anti-human integrin a2 monoclonal P1E6, Chemicon, San Francisco, CA, USA). For Q-PCR SYBR GreenER qPCR SuperMix was used with the ABI PRISM and the experiments performed according to the manufacturer's instructions. The following PCR primers were used: LMO2 forward: 5 0 -CAGAGGCGTCAGTGA GACAG-3 0 , LMO2 reverse: 5 0 -TTGAAGTCTCCAGCCACCAT-3 0 , BCL-2 forward: 5 0 -AGATGCTTTTTGTAGCTCAGTTG-3 0 and BCL-2 reverse: 5 0 -GAGGCAGGGTCTCATGTAGC-3 0 , for the nonspecific genomic DNA control that co-precipitates during the ChIP procedure a region from glyceraldehydes-3 phosphate dehydrogenase was chosen glyceraldehydes-3 phosphate dehydrogenase forward: 5 0 -TGGACAGCACTGACTTCCAG-3 0 and glyceraldehydes-3 phosphate dehydrogenase reverse 5 0 CAAAGCATCGAC CAGTGCTA-3 0 . The comparative CT method was used to calculate the fold enrichment between experimental and non-specific genomic DNA.
Retroviral transduction of primary hematopoietic cells c-Kit
þ HPCs were enriched using anti-c-Kit-biotin (2B8, BD Pharmingen, Oxford, UK) from the fetal liver of E13.5 C57Bl/6 mouse embryos by magnetic cell sorting (Miltenyi Biotec, Oxford, UK). Retroviral transduction was performed as previously described. 24 
Methylcellulose assays
HPCs transduced with retroviral constructs were cultured in duplicate 1.1 ml methylcellulose cultures in 35 mm 2 plates for 48 h after infection as previously described. 24 For B-cell assays, cells were cultured in Methocult M3231 (Stem Cell Technologies, Sheffield, UK) supplemented with 100 ng ml
À1
of stem cell factor (SCF), 20 ng ml À1 of interleukin-7 (IL-7) and 10 ng ml À1 of fms-like tyrosine kinase-3 ligand (Flt3 l). All cytokines were purchased from Peprotech EC (London, UK).
RT-PCR
TaqMan Gene Expression Assays were used according to standard Applied Biosystems (Cheshire, UK) and in quadruplicate for each sample, list of product IDs were available on request. The comparative CT method (delta-delta method) was used to calculate the fold differences between experimental and control samples. Statistical analyses were carried out using the Student's t-test (two-sided equal variance).
Western blotting analysis
Western blotting analysis was carried out as previously described using mouse anti-BCL-2 monoclonal antibody (sc-509, Santa Cruz Biotechnology, Heidelberg, Germany), mouse anti-E2A (Yae) monoclonal antibody (Santa Cruz Biotechnology), mouse anti-Myc (9B11) monoclonal antibody (Cell Signaling, Hitchin, UK) or mouse anti-b-Actin (A1978) monoclonal antibody (Sigma-Aldrich, Poole, Dorset, UK). 23 
Flow cytometric analysis
Cells were pre-incubated with unlabeled anti-Fcg III/II receptor mAb2.4G2 diluted in fluorescence-activated cell sorting staining buffer (phosphate-buffered saline containing 0.1% bovine serum albumin and 0.1% sodium azide. Cells were stained with B220 (RA3-6B2), BP1 (6C3), cKit (2B8), CD19 (1D3) and CD127 (A7-R34).
Cell proliferation assays 1 Â 10 5 lymphoid cells in a final volume of 100 ml were dispensed in triplicate into wells of a 96-well flat-bottomed plate. Cell viability was measured using MTS assay (Promega, Southampton, UK). For BCL-2 inhibition studies, ABT-737 and its enantiomer (gifts from Abbott Laboratories, Maidenhead, Kent, UK) were dissolved in dimethyl sulfoxide and used at a final concentration of up to 1000 nM.
Retroviral generation and expression of Lmo2 shRNAmir
The MSCV-LTRmiR30-PIG (called shRNAmir from now on) retroviral vector that enables the efficient expression of shRNA from RNA Polymerase II promoters was used. 25 shRNAs were designed with RNAi Central and LMO2 (5 0 -ACCACAGATTGTTTCTAT ACAA-3 0 ), as well as a validated non-silencing control (RHS1707; Open Biosystems, Huntsville, AL, USA) were cloned into the shRNAmir vector.
Results

Identification of transcriptional targets of E2A-HLF
DNA microarray studies were carried out to identify genes regulated by E2A-HLF. Individual clones of BaF3 cells have previously been generated with tetracycline-inducible E2A-HLF expression. 23 Three independent BaF3 clones were chosen and cultured in the presence of doxycycline for 12 h to induce expression of E2A-HLF as confirmed by Western blot (data not shown). Microarray data were filtered by Welch's t-test to identify 26 genes that were statistically significantly upregulated greater than 1.3-fold, and 20 genes that were downregulated more than E2A-HLF acts via Lmo2 and Bcl-2 J de Boer et al Tables 1 and 2 ). E2A-HLF is a transcriptional activator 4-8 hence, we concentrated on candidate target genes for which expression was upregulated. E2A-HLF is thought to induce leukemogenesis following inappropriate activation of genes triggered through the HLF bZip DNA binding and dimerization domain. 9 Previous work has shown that wildtype HLF regulates the expression of Lmo2 and Bcl-2 in hematopoietic cells. 26, 27 Furthermore, there is an established role for Lmo2 in T-cell leukemia 28 and Bcl-2 in B-cell leukemia. 29 Therefore, we focused our attention on these two genes. We analyzed LMO2 and BCL-2 expression in materials from patients with B-precursor ALL. RT-PCR using LMO2-and BCL-2-specific primers was performed on cDNA prepared from four B-precursor ALL bone marrow biopsies (two E2A-HLF rearranged and two non E2A-HLF rearranged) and human cell lines ( Figure 1a ).
1.3-fold by E2A-HLF (Supplementary
Upregulation of both Lmo2 and Bcl-2 was seen in all E2AFHLF-positive samples compared with control samples. In addition, we measured the protein levels of BCL-2 and found them to be elevated by 1.5-1.6-fold in the E2AFHLF-positive human cell lines relative to the control human cell lines without E2A-HLF rearrangement ( Figure 1a , lower panel). These data suggest that LMO2 and BCL-2 are regulated by E2A-HLF in primary human B-precursor ALL. The mechanism and functional significance of Lmo2 and Bcl-2 regulation was further assessed.
Lmo2 and Bcl-2 are direct targets of E2A-HLF
The gene array experiments demonstrate that E2A-HLF can rapidly alter the expression level of several genes (within 12 h of the addition of doxycycline). It is possible that within the Immunoprecipitates were subjected to PCR with primer pairs specific to parts of the Lmo2 or Bcl-2 promoter. PCR was also performed with total chromatin input (labeled Input). (c) E2A-HLF upregulates Lmo2 and Bcl-2 in primary HPCs. HPCs were transduced with E2A-HLF retrovirus cultured in methylcellulose containing 100 ng/ml of stem cell factor (SCF), 20 ng/ml of IL-7 and 10 ng/ml of Flt3L for 7 days. Lmo2 and Bcl-2 RNA levels were quantified using Q-PCR. Lmo2 and Bcl-2 levels were normalized to Gapdh mRNA and are presented relative to RNA levels in cells transduced with Neo control.
E2A-HLF acts via Lmo2 and Bcl-2 J de Boer et al timeframe of this experiment, secondary targets are upregulated, therefore, we used ChIP to examine whether E2A-HLF binds directly to the promoter regions of Lmo2 and Bcl-2. To achieve this, MSCV-based retroviral constructs were created that overexpress Myc-tagged E2A-HLF (Supplementary Figure 1a) . BaF3 cells were transduced with either Myc-tagged E2A-HLF or empty vector (Neo) control. ChIP was performed with antibodies that recognize either the Myc epitope or an irrelevant protein.
PCR primers were designed that spanned potential conserved HLF binding sites in the distal Lmo2 (5 0 -CAGA-3 0 /5 0 -GTGATGT AAT-3 0 ) and Bcl-2 (5 0 -AGTTGTACAATA-3 0 ) promoters. Specific enrichment of the distal Lmo2 promoter was obtained using the E2AFHLF-transduced BaF3 cells (Figure 1b) . Weaker, but significant enrichment of the Bcl-2 promoter was also obtained (Figure 1b) . No enrichment was obtained in the absence of E2A-HLF or when using a non-specific antibody demonstrating the specificity of the ChIP. These data were confirmed by Q-PCR showing the enrichment of the E2A-HLF binding sites relative to that of non-specific genomic DNA that co-precipitates during the ChIP procedure (Figure 1b) .
The t(17;19) translocation is associated with childhood leukemia and the overwhelming body of evidence shows that almost all such translocations arise in human HPCs. 32 Hence, we used murine HPCs to confirm the regulation of both Lmo2 and Bcl-2 as targets by E2A-HLF. HPCs were transduced with either E2A-HLF or Neo control and cultured for 7 days in methylcellulose containing the lymphoid-promoting growth factors SCF, IL-7 and Flt3L. Expression of both the Lmo2 (B11-fold) and Bcl-2 (Btwo-fold) mRNAs was found to be upregulated in E2AFHLF-expressing cells, compared with control ( Figure 1c ). These data show that both Lmo2 and Bcl-2 are direct targets of E2A-HLF and their expression is induced in HPCs, the likely target cell population for leukemogenesis.
Expression of E2A-HLF alone is sufficient to immortalize hematopoietic progenitors
The ability of leukemia-associated oncogenes to immortalize and transform myeloid and lymphoid progenitor cells is assessed using colony-forming cell assays in methylcellulose (Supplementary Figure 1b) . 33 E2A-HLF was previously shown to be only able to immortalize lymphoid cells when co-expressed with Bcl-2 and grown on a supporting stromal layer. 10 As E2A-HLF expression alone leads to ALL in children, we needed to generate a model system in which only expression of E2A-HLF could immortalize lymphoid progenitors. c-Kit þ -enriched E13.5 fetal liver HPCs were isolated, infected by retrovirus and then cultured in methylcellulose enriched with SCF, IL-7 and Flt3L and allowed serial replating (Figure 2a) . The typical colonies generated by E2A-HLF were much larger and more densely packed with cells than those generated by empty vector (Figure 2b ). These cells proliferated readily when transferred from methylcellulose to liquid culture (data not shown). Flow cytometry of E2A-HLF immortalized cell lines showed expression of the pre-B-cell surface markers CD19, B220, BP1 and c-Kit (Figure 2c) . To determine the cytokine requirements of E2A-HLF cell lines, cell proliferation assays were carried out using different combinations of cytokines (Figure 2d ). E2A-HLF immortalized cell lines grew in response to SCF and IL-7 combined, but could not grow in the absence of either SCF or IL-7. E2A-HLF was also able to immortalize Lin À c-Kit þ -sorted cells from murine adult bone marrow (data not shown). These data show that expression of E2A-HLF alone is sufficient to immortalize HPCs in conditions permitting the maintenance of early B-cell progenitors.
E2A-HLF target genes function synergistically to immortalize lymphoid progenitors
We tested whether the candidate target genes Lmo2 and Bcl-2, either alone or in combination, constituted elements of the pathway downstream of E2A-HLF that contribute to the immortalized phenotype. Co-expression of Lmo2 and Bcl-2 was able to immortalize lymphoid progenitors derived from E13.5 fetal liver HPCs in serial replating assays in methylcellulose (Figure 3a) . However, expression of either Lmo2 or Bcl-2 alone in HPCs was unable to immortalize these cells. The morphology of colonies generated by Lmo2 and Bcl-2 was typically larger than normal pre-B-cell colonies, but differed from E2A-HLF colonies in that they had slightly less compact morphology (Figure 3b) . Western blotting confirmed co-expression of both LMO2 and BCL-2 within the immortalized cells ( Figure 3c) . As with the E2A-HLF immortalized cells, Lmo2 and Bcl-2 immortalized cell lines also expressed the early B-cell progenitor markers CD19, B220, c-Kit and BP1 (Figure 3d) . The cytokine requirements of these cell lines were also assessed. Lmo2 and Bcl-2 cell lines were able to survive in the absence of growth factors, but proliferated maximally in the presence of SCF, IL-7 and Flt3L (Figure 3e ). However, these cells also proliferated with only IL-7 most likely as a result of the higher IL-7 receptor expression on the cell surface of the Lmo2 and Bcl-2 cell lines (Figure 3f ), compared with the E2AFHLF-expressing cell lines. This might indicate that expression of the Il-7r gene is a target of LMO2 rather a direct target of E2A-HLF.
These data suggest that Lmo2 and Bcl-2 are two important downstream targets of E2A-HLF and forced overexpression of Lmo2 and Bcl-2 is capable of replicating the immortalizing action of E2A-HLF. Although transducing HPCs with the individual genes inevitably leads to higher expression levels than that induced by E2A-HLF alone, nevertheless, these data show that Lmo2 and Bcl-2 could have a direct role in E2A-HLF immortalization. Therefore, blocking or inhibiting the action of Lmo2 or Bcl-2, or both, could be deleterious to the survival of E2A-HLF immortalized lymphoid cells or at least sensitize them to other chemotherapeutic agents. In order to test this hypothesis we set out to block both Lmo2 and Bcl-2 function in E2A-HLF immortalized cell lines.
Lmo2 knockdown leads to loss of E2A-HLF immortalized cells
The most feasible method to interfere with Lmo2 expression was by shRNA-mediated knockdown. Retroviral vectors were generated expressing shRNAs designed to knockdown Lmo2. The E2A-HLF immortalized cells were infected with these retroviral constructs and the effect on endogenous Lmo2 expression validated by Q-PCR. An shRNA was identified that was highly efficient at knocking down Lmo2 expression (LMO2-shRNAmir) relative to control non-silencing-shRNAmir (Figure 4a and data not shown). HPCs from E13.5 fetal liver were infected with the LMO2-shRNAmir or non-silencingshRNAmir, 24 h later infected with either the E2A-HLF or Neo retroviral expression vector and then plated in methylcellulose under lymphoid conditions. HPCs infected with E2A-HLF and non-silencing-shRNAmir were immortalized. However, previous exposure to LMO2-shRNAmir abrogated E2A-HLF's ability to immortalize lymphoid progenitors (Figure 4b ) thus, suggesting a requirement for Lmo2 downstream of E2A-HLF in the initiation of cellular immortalization. We then knocked down Lmo2 expression in E2A-HLF immortalized cells in order to test whether its requirement for maintenance of immortalization and hence, a valid target for t(17;19) harboring leukemia cells. E2A-HLF immortalized lymphoid progenitors were passaged in liquid culture and then infected with the LMO2-shRNAmir or non-silencing control. The shRNAmir expression vectors expressed green fluorescent protein, therefore, the viability of cells targeted for Lmo2 knockdown was monitored via changes in the proportion of green fluorescent protein-positive cells. The percentage of green fluorescent protein-expressing cells was reduced rapidly indicating the necessity for high levels of Lmo2 expression in E2A-HLF immortalized cells (Figure 4c ). To ensure that the observed effects were due to Lmo2 knock down and not 'off target' effects, a knockdown rescue experiment was performed. The LMO2-shRNAmir binds in the 3 0 -untranslated region of Lmo2 so the expression of Lmo2 can be rescued with the LMO2 retroviral vector containing only the open reading frame of Lmo2. Overexpression of Lmo2 completely blocked the effect of LMO2-shRNAmir on E2AFHLF-expressing cells (Figure 4c ). These data suggest that E2AFHLF-mediated immortalization of lymphoid progenitors is directly dependent on Lmo2.
Inhibition of BCL-2 in E2A-HLF cells leads to sensitization to doxorubicin
The effect of inhibiting BCL-2 function in cell lines immortalized by E2A-HLF or by Lmo2 and Bcl-2 was assessed using the small-molecule inhibitor, ABT-737 in cell proliferation assays. ABT-737 is a specific inhibitor of BCL-2, BCL-X L and BCL-w, which acts by binding to the hydrophobic BH3-binding groove of these homologous anti-apoptotic molecules. 34 The less potent enantiomer bearing the opposite configuration of the dimethylaminoethyl group was used as a negative control. 34 E2A-HLF and Lmo2 and Bcl-2 immortalized cell lines were treated with varying concentrations of ABT-737. Cell viability was inhibited at 100 to 1000 nM of ABT-737 (Figures 5a and b) . The same concentration of the enantiomer did not show any adverse effect on cell proliferation. The proliferation of Bcl-2-negative lymphoma cell line S49.1 was not affected by increasing concentrations of either ABT-737 or the enantiomer (Figure 5c ). We determined whether ABT-737 would be able to sensitize a panel of human leukemic cell lines that express E2A-HLF or an unrelated fusion, ETV6-RUNX1, as well as the primary mouse B-cell progenitor cells immortalized by E2A-HLF or Lmo2 and Triplicate cultures of cells maintained in the presence or absence of 100 ng/ml of SCF, 20 ng/ml of IL-7 and/or 10 ng/ml of Flt3L. After 48 h, cell proliferation was quantified using MTS assay.
E2A-HLF acts via
increasing doses of doxorubicin (which functions by causing DNA damage and commonly used to treat childhood leukemia) in the presence of 100 nM of ABT-737, a dose that has little effect on the proliferation of cell lines derived from murine HPCs ( Figure 5 ). ABT-737 did not sensitize non-transduced pre-B cells grown in methylcellulose (Figure 6a ) or the S49.1 cell line (Figure 6b ) to the effects of doxorubicin. The E2A-HLF-immortalized cell line was particularly sensitive to the combined effects of doxorubicin and ABT-737, and it was necessary to lower the doxorubicin concentration range to nM rather than mM for this cell line (Figure 6c) . The Lmo2-and Bcl-2-immortalized cell line was also sensitized to doxorubicin by ABT-737 (Figure 6d 
) translocation were sensitized as was the REH line bearing the t(12;21) translocation (Figure 6g ). These data suggest that ABT-737 may sensitize transformed or immortalized leukemic cells irrespective of the initiating oncogene, whereas non-transformed cells or cells that express low levels of BCL-2 are not sensitized. ABT-737 presents a therapeutic window so that, used in combination, it will allow chemotherapeutic drugs to function more effectively and at lower doses. This is particularly applicable to t(17;19) leukemias as they have elevated BCL-2 levels that appear to contribute to their leukemic phenotype. 10 
Discussion
The t(17;19) childhood B-precursor ALL has an extremely poor prognosis. 1, 21, 22 We set out to examine the mechanism, whereby the t(17;19) fusion product, E2A-HLF, leads to leukemogenesis in lymphoid progenitors and to identify therapeutic targets for novel treatments to improve the prospects of t(17;19) patients. The oncogenic activity of E2A-HLF requires the abnormal localization of the trans-activation domains of E2A to the leucine zipper dimerization domain of HLF 16 and the consequent alteration in the transcriptional profile of normal HPCs. 9 Using an inducible expression system of the fusion protein in mouse B-precursor ALL cells, we identified candidate E2A-HLF target genes, of these Lmo2 and Bcl-2 were of particular interest as both have been previously identified as being regulated by wild-type HLF in hematopoietic cells 26, 27 and both have established roles in other leukemias. 28, 29 We showed that, Lmo2 and Bcl-2 are direct targets of E2A-HLF and both are highly upregulated by E2A-HLF during the first stages of immortalization in HPCs. More importantly, we have shown that the expression of both LMO2 and BCL-2 is significantly upregulated in primary B-precursor ALL biopsy material from t(17;19) patients compared with non-t(17;19) controls. We established a model system so that E2A-HLF alone could immortalize HPCs in methylcellulose. These cells have a characteristic B-precursor ALL phenotype, B220
þ , c-Kit
þ and CD19 þ , as well as IL-7 and SCF dependence. It should be noted that the E2A-HLF immortalized cell lines did not cause leukemia up to 9 months after injection into NOD/ SCID mice (data not shown), perhaps because the loss of one E2A allele is required in addition to abnormal expression of the HLF DNA-binding domain to fully induce leukemia. 9 Downstream E2A-HLF targets could potentially function alone or in combination to promote leukemogenesis. However, on the basis of the precedent that as few as two oncogenes can function in synergy to immortalize cells 35, 36 we found that Lmo2 and Bcl-2 could synergize highly effectively to immortalize lymphoid progenitor cells with a similar phenotype from that of E2A-HLF alone. Immortalization is only one, albeit crucial step of the leukemogenic process. Future work should examine how LMO2 and BCL-2 interact with previously identified candidate targets of E2A-HLF, such as GROUCHO and SLUG, and how this might contribute to the phenotype of t(17;19) leukemia.
The next step was to determine whether the E2A-HLF function is actually dependent on the target genes and whether manipulation of the targets might be of therapeutic value. Downregulation of the level of Lmo2 in E2A-HLF-immortalized cells leads to the loss of the immortalized cells. Targeting the activity of BCL-2 by ABT-737 in transformed or immortalized leukemia cells sensitized the cells to the effects of chemotherapeutic agents, such as doxorubicin. 
E2A-HLF acts via
We have characterized a part of the molecular pathway downstream of E2A-HLF leading to leukemia. Our aim is not to suggest a therapeutic approach only effective for t (17;19) , but one that could also be effective for other types of childhood ALL. We have shown that the combination of ABT-737 and doxorubicin can be effective in ETV6-RUNX1-expressing leukemic cells. Lmo2 has been found, by gene expression profiling, to be upregulated in patients with B-cell leukemias harboring MLL rearrangements 37 in MLL-ENL-immortalized cells. 38 The upregulation of Lmo2 expression in MLL leukemias and by E2A-HLF suggests that Lmo2 may be involved in a common leukemogenic pathway.
It is likely that cancer maintenance requires the expression of only a small set of critical genes that, therefore, present attractive targets for cancer therapy. In childhood leukemia, Bcl-2 and Lmo2 may be members of this common set of targets. It would appear that the 'oncogene addiction' engendered by E2A-HLF is at least partially due to Bcl-2 and Lmo2. Therefore, although deregulated expression of Lmo2 and Bcl-2 are elements of other leukemias, targeting both Lmo2 and Bcl-2 could be of particular benefit to t(17;19) patients. The finding regarding LMO2 is further supported by a recent study (published since this work was submitted) that also shows that E2A-HLF is capable of inducing LMO2 expression. 39 
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